HRX-0233

Customer Review

Based on 1 Customer Validation

HRX-0233 is a small-molecule MAP2K4 inhibitor. HRX-0233 results in strong tumor shrinkage without any apparent toxicity in H358 KRASG12C-mutant non-small cell lung cancers (NSCLC) in vivo. HRX-0233 efficiently prevents feedback activation of receptor tyrosine kinases (RTKs) upon monotherapy KRAS inhibitor Sotorasib (HY-114277) and causes a more sustained and complete inhibition of MAPK signaling. HRX-0233 is promising for research of AR-negative prostate cancer, lung and colon cancers.

For research use only. We do not sell to patients.

  • Purity: 98.92%
  • CAS No.: 2409140-12-9
  • Formula: C24H21F2N5O3S
  • Molecular Weight:497.52
  • Storage:
    Powder   -20°C, 3 years ; In solvent   -80°C, 6 months , -20°C, 1 month
  • Biological Activity
  • Chemical Information
  • Solvent & Solubility
  • Purity & Documentation
  • References
  • Help & FAQs
100 mg
Get Quote In-stock
Please select quantity
Price: USD 0.00